

## **REMARKS/ARGUMENTS**

### **Restriction Requirement**

The Examiner has required restriction to one of the following inventions:

- |            |   |
|------------|---|
| Group I    | Claims 1-6, drawn to nucleic acids encoding polypeptide.  |
| Group II   | Claims 7-9 and 12-15 (in part), drawn to polypeptide.   |
| Group III  | Claims 10-11 and 12-15 in part, drawn to antibodies.  |
| Group IV   | Claims 12-15 (in part), drawn to agonists.  |
| Group V    | Claims 12-15 (in part), drawn to antagonists.   |
| Group VI   | Claims 16-17 (in part), drawn to a method of treating immune disorder with a polypeptide.                           |
| Group VII  | Claims 16-17 (in part), drawn to a method of treating immune disorder with an agonist.                              |
| Group VIII | Claims 16-17 (in part), drawn to a method of treating immune disorder with an antagonist.                           |
| Group IX   | Claims 16-17 (in part), drawn to a method of treating immune disorder with an antibody.                             |
| Group X    | Claim 18, drawn to a method of determining the presence of a polypeptide.   |
| Group XI   | Claim 19, drawn to a method of diagnosing an immune related disease by detecting a level of expression.             |
| Group XII  | Claim 20, drawn to a method of diagnosing an immune related disease using an antibody.                              |
| Group XIII | Claim 21, drawn to a method of identifying a compound that inhibits by determining lack of responsiveness.          |
| Group XIV  | Claim 22-23, drawn to a method of identifying a compound that inhibits by determining lack of expression of a gene. |
| Group XV   | Claim 24, drawn to a method of identifying a compound that mimics the activity of the polypeptide.                  |
| Group XVI  | Claim 25, drawn to a method of stimulating the immune response in a mammal.   |

Group XVII Claim 25, drawn to a method of diagnosing an inflammatory immune response in a mammal.

Group XVIII Claim 27, draw to a method of differentiating monocytes.

The Examiner has also required that a SEQ ID NO: be elected.

Applicants elect Group III, Claims 10-11 and 12-15 (in part), drawn to an antibody to the polypeptide, and a composition and an article thereof. Applicants further elect SEQ ID NO:592 (PRO12828), which is encoded by SEQ ID NO:591 (DNA150977) for the elected claims.

Applicants have canceled Claims 1-9 and 16-27, which are directed to non-elected inventions. Claim 10 has been amended to be an independent claim. The amendments is fully supported by the specification and claims originally filed. Applicants reserve the right to pursue the subject matters in the canceled claims in a continuation, continuation-in-part, or divisional application. Claims 10-15 are pending after the amendments. Applicants respectfully request that the Examiner consider the amendments.

### CONCLUSION

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned agent at the telephone number shown below.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39766-0271 R1). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

Date: November 20, 2007

By: \_\_\_\_\_

Panpan Gao (Reg. No. 43,626)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638  
SV 2317162 v1 (39766.0271)